Raymond James Upgrades Tvardi Therapeutics to Outperform, Sets $10 Target on Strong TTI-109 Data

Tvardi’s new drug TTI-109 showed strong early results, fewer side effects, and potential in autoimmune diseases, boosting investor confidence.